Show simple item record

A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorBrunsvig, P
dc.contributor.authorHelland, A
dc.contributor.authorSegarra, NV
dc.contributor.authorAix, SP
dc.contributor.authorCosta, EC
dc.contributor.authorGomez, MD
dc.contributor.authorPerez, JMT
dc.contributor.authorArriola, E
dc.contributor.authorCampelo, RG
dc.contributor.authorSpicer, J
dc.contributor.authorThompson, J
dc.contributor.authorGranados, ALO
dc.contributor.authorHolt, R
dc.contributor.authorLorens, J
dc.contributor.authorShoaib, M
dc.contributor.authorSiddiqui, A
dc.contributor.authorSchmidt, E
dc.contributor.authorChisamore, M
dc.contributor.authorFelip, E
dc.date.accessioned2020-01-29T15:17:44Z
dc.date.available2020-01-29T15:17:44Z
dc.date.issued2019en
dc.identifier.citationKrebs MG, Brunsvig P, Helland A, Segarra N, Aix S, Costa E, et al. A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis. Journal for Immunotherapy of Cancer. 2019;7en
dc.identifier.urihttp://hdl.handle.net/10541/622634
dc.language.isoenen
dc.titleA phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentChristie NHS Foundation Trust and The University of Manchester, Manchester,en
dc.identifier.journalJournal for Immunotherapy of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record